




Title of Invention

(Below is limited to 1-page only; be careful not to disclose vital technology content. Please delete these words when the document is finished)

PI : Prof. Wei-Li Chen
 Professor in Ophthalmology
 Medicine College, National Taiwan Univeristy.

Experience:

Resident, National Taiwan University Hospital
 Attending, National Taiwan University Hospital
 Postdoctoral fellow, Schepen Eye Research Institute, Boston,
 Invited Research Assistant professor, University of Cincinnati
 Professor, National Taiwan University Hospital



Market Needs: Eye drops market and patient demand.

Our Technology: It is found in the study that human platelet lysate (HPL) has corneal neurotrophic abilities, particularly the efficacy in repairing corneal nerve injury, and HPL can be used as topical eye drop to treat neurotrophic keratopathy, dry eye and corneal epithelial defects in place of human peripheral serum (HPS) and fetal bovine serum (FBS) °

Strength: Provide an efficient treatment strategy to treat corneal diseases related to corneal nerve injury, shorten the time of clinical autologous serum preparation, reduce the burden on paramedics and patients, and reduce the cost.

Competing Products: Currently, there are no competitive products on the market.

Intellectual Properties: Preparing for patent filing

Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU
 Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw